BioNTech (NASDAQ:BNTX) Trading 1.3% Higher – Still a Buy?

BioNTech SE (NASDAQ:BNTX) rose 1.3% during mid-day trading on Thursday . The company traded as high as $103.98 and last traded at $103.46. Approximately 167,580 shares traded hands during trading, a decline of 79% from the average daily volume of 807,735 shares. The stock had previously closed at $102.14.

Analysts Set New Price Targets

BNTX has been the subject of a number of research analyst reports. Jefferies Financial Group upgraded shares of BioNTech from a “hold” rating to a “buy” rating and raised their price objective for the stock from $96.00 to $150.00 in a report on Tuesday, September 17th. UBS Group lifted their target price on shares of BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 18th. HC Wainwright reiterated a “buy” rating and issued a $150.00 target price on shares of BioNTech in a research note on Monday, November 18th. TD Cowen reduced their price objective on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a research note on Tuesday, November 5th. Finally, Morgan Stanley raised shares of BioNTech from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $93.00 to $145.00 in a research note on Tuesday, September 24th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, BioNTech currently has a consensus rating of “Moderate Buy” and an average target price of $138.79.

BioNTech Stock Up 4.5 %

The stock’s fifty day moving average is $113.60 and its 200 day moving average is $97.70. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $27.12 billion, a P/E ratio of -53.87 and a beta of 0.26.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.24 billion during the quarter, compared to analyst estimates of $514.08 million. During the same period in the prior year, the business posted $0.73 EPS. The firm’s revenue was up 38.9% compared to the same quarter last year. Research analysts predict that BioNTech SE will post -3.68 EPS for the current fiscal year.

Institutional Investors Weigh In On BioNTech

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FMR LLC increased its position in BioNTech by 797.8% during the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company’s stock valued at $748,243,000 after purchasing an additional 5,598,190 shares during the period. Fred Alger Management LLC purchased a new stake in shares of BioNTech in the 3rd quarter worth about $59,485,000. Candriam S.C.A. lifted its position in shares of BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after purchasing an additional 418,695 shares during the period. Point72 Asset Management L.P. lifted its position in shares of BioNTech by 283.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock worth $37,103,000 after purchasing an additional 341,311 shares during the period. Finally, Braidwell LP purchased a new stake in shares of BioNTech in the 3rd quarter worth about $29,425,000. 15.52% of the stock is currently owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.